Partnership marks AbbVie's entrance into the obesity field Agreement will enable the incorporation of GUB014295, an amylin peptide discovered and developed by Gubra, into AbbVie's global infrastructure for developing and commercializing therapies for patients in need NORTH CHICAGO, Ill....
Hence then, the article about abbvie and gubra announce license agreement to develop an amylin analog for the treatment of obesity was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( AbbVie and Gubra Announce License Agreement to Develop an Amylin Analog for the Treatment of Obesity )
Also on site :
- Soul Hitmaker Behind One of the ‘Greatest’ 1974 R&B Chart-Toppers “Let’s Straighten It Out,” Dies at 86
- Doctor who reportedly wrote a paper on violent teens killed in alleged plot involving her daughter and friends
- Katie Miller throws Karoline Leavitt a party with White House lectern cake as speculation continues over replacement